Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration to begin human clinical trials with its drug candidate, Vivecon™ (MPC-9055), for the treatment of AIDS.
